Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017

The “Chimeric Antigen Receptor (CAR) T cell Immunotherapy -Pipeline Insights 2017″ report provides a comprehensive analysis of CAR-T cellprofiles currently undergoing clinical studies. It covers detailed drug profiles of potential CAR-T across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline CAR-T cell immunotherapies by cancer type. In addition to analysis on active pipeline molecules, the report also provides a detailed information about discontinued and dormant drugs.

View report: https://arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017

The report profiles key players in developing potential CAR-T cell Immunotherapy candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Scope

Provides in-depth insights about active Chimeric Antigen Receptor (CAR) T cell pipeline drug candidates

Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery

Provides pipeline assessment by cancer type

Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner

Analyzes key players involved in clinical research and development of the Chimeric Antigen Receptor (CAR) T cell immunotherapy

Provides the coverage of key news related to Chimeric Antigen Receptor (CAR) T cell immunotherapy, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

CAR-T cell immunotherapy represents one of a major breakthrough in cancer research. For decades, the cornerstones of cancer treatment have been chemotherapy, surgery, and radiation therapy. Over the past decade, targeted therapies and immunotherapies have changed cancer treatment paradigm.

The CAR-T cell therapy, a form of immunotherapy, is a novel adoptive antitumor treatment. Ideally, CAR-T cells can particularly localize and destroy tumor cells by interacting with the tumor specific antigens located on tumor cell surface.

CAR-T cell therapy showed promising results in the treatment of haematological malignancies and solid tumors. The third generation of CAR-T cell therapy demonstrates increased antitumor cytotoxicity and persistence through modifying the structureof CAR-T cells. In this report, we mentioned the preclinical and clinical progress of CAR-T cells targeting various variants including EGFR, human epidermal growth factor receptor 2 (HER2), and mesothelin (MSLN).

The manufacturing of CD19 CAR T cell immunotherapy CTL019 is in a way which will reform the process of using the CAR T cell therapy globally. The anticipation of regulatory and manufacturing challenges before they rise and proactively addressing the disquiets helps to hasten the process of bringing this promising novel approach to more patients in future. Few of other promising CAR T cell candidates currently in the pipeline are KTE-C19, JCAR020, JCAR 024, JCAR015, JCAR017, UCART19, S68587, UCART123, MB-101, bb2121, PCAR-119, anti-CD19 CAR-NK cells, MB-102, AU-101, huCART19, huCTL019, BPX-401 (CIDeCAR), OXB-302, ICG-122, CD4CAR, ICG-124, CD5CAR, ICG-142, ICG-140, ICG-138/ICG-139, ICG-136. Few of the key companies which are involved in the development of CAR-T cell therapy include Amgen, CARsgen, Celgene, Cellectis, Humorigin, iCell Gene, Innovative Cellular Therapeutics, Intellia Therapeutics, Intrexon, J&J, Kite Pharma, MabVax, MaxCyte, Novartis, Oncternal, Opus Bio, Pfizer, Sorrento, Takara and Ziopharm.

Reasons to Buy

To gain erudite insights about the Chimeric Antigen Receptor (CAR) T cell immunotherapypipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

Related Report
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017

https://arizton.com/reports/pharma-pipeline-analysis/anaplastic-lymphoma-kinase-alk-inhibitors-pipeline-insights

Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.